Literature DB >> 31629843

Managing Peripheral Artery Disease in Diabetic Patients: A Questionnaire Survey from Vascular Centers of the Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS).

Umberto Marcello Bracale1, Raffaele Pio Ammollo2, Emad A Hussein3, Jamal J Hoballah4, Olivier Goeau-Brissonniere5, Maurizio Taurino6, Carlo Setacci7, Felice Pecoraro8, Giancarlo Bracale2.   

Abstract

BACKGROUND: The Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS) was founded on October 1, 2018, to enhance cooperation among vascular professionals within Mediterranean countries. Due to its prominent social and economic impact on national health systems, diabetic arteriopathy has been selected as the very first topic to be investigated by the federation.
METHODS: MeFAVS members were asked to reply to a questionnaire on the management of diabetic ischemic foot. Results were collected and analyzed statistically. The questionnaire consisted of 15 multiple choice answers regarding diabetic foot (DF) diagnosis and treatment. The questionnaire was submitted to 21 centers on April 20, 2019.
RESULTS: Response rate was 62%. The survey revealed that vascular surgeons, diabetologists, and wound care nurses made-up the core of the diabetic teams present in 76.9%, 69.3%, and 92.3% of the centers, respectively. Diabetic teams were most often led by vascular surgeons (53.8%) and diabetologists (42.2%), but only in 7.9% of cases by nurses. Duplex ultrasonography and computed tomographic angiography were the most commonly available tools used to assess diabetic peripheral arterial disease (PAD). Surgical wound care was undertaken by vascular surgeons in the majority of cases, and only in 46.2% of the cases to orthopedic or plastic surgeons, while nonsurgical wound care was handled by specialized nurses (76.6%) and diabetologists (53.8%). First-line revascularization was preferred over conservative treatment (61.5% vs 53.8%) and endovascular strategy (45.3%) over open (33.7%) or hybrid (21.0%) surgery. Vascular surgeons and interventional radiologists were found to be the most common performers of endovascular revascularization (92.3% and 53.8%, respectively). Amputations had an overall rate of 16.6% (range 4-30%) and a mean reintervention rate of 22.5%, and were usually performed by vascular surgeons for both minor and major interventions (84.6%) followed by orthopedic surgeons (15.4% minor and 30.8% major). The availability of a DF clinic (84.6%) and endovascular (53.8%) and open surgery (46.2%) capabilities were considered fundamental to reduce amputation rates.
CONCLUSIONS: Especially since the introduction and spreading of new endovascular techniques for the treatment of DF, it is a common consensus amongst vascular surgeons that a standardized approach to the discipline is necessary in order to improve outcomes such as amputation-free survival and mortality and it is with this perspective and purpose that transnational cooperation amongst vascular professionals and residents in training are aiming for greater proficiency in endovascular and open surgery.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31629843     DOI: 10.1016/j.avsg.2019.09.013

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  3 in total

1.  The Influence of Diabetes Mellitus on the Outcome of Superficial Femoral Artery Recanalization is Debatable.

Authors:  L Rizzo; A D'Andrea; N Stella; P Orlando; M Taurino
Journal:  Transl Med UniSa       Date:  2020-02-20

2.  Focusing on Diabetic Ulcers.

Authors:  C Setacci; D Benevento; G De Donato; E Viviani; U M Bracale; L Del Guercio; G Palasciano; F Setacci
Journal:  Transl Med UniSa       Date:  2020-02-20

3.  The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience.

Authors:  Ettore Dinoto; Francesca Ferlito; Manfredi Agostino La Marca; Graziella Tortomasi; Francesca Urso; Salvatore Evola; Giovanni Guercio; Marco Marcianò; David Pakeliani; Guido Bajardi; Felice Pecoraro
Journal:  Diagnostics (Basel)       Date:  2022-02-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.